Published in Circulation on September 06, 2011
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res (2014) 2.24
Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation (2014) 2.07
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev (2014) 1.96
Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging (2014) 1.75
Remote ischemic conditioning. J Am Coll Cardiol (2015) 1.66
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med (2013) 1.55
Iodide protects heart tissue from reperfusion injury. PLoS One (2014) 1.40
Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide. J Am Heart Assoc (2012) 1.14
Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc Natl Acad Sci U S A (2013) 1.12
Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol (2011) 1.08
Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol (2016) 1.08
Concise review: heart regeneration and the role of cardiac stem cells. Stem Cells Transl Med (2013) 1.08
Remote ischemic preconditioning confers late protection against myocardial ischemia-reperfusion injury in mice by upregulating interleukin-10. Basic Res Cardiol (2012) 1.05
Cardioprotection during cardiac surgery. Cardiovasc Res (2012) 1.03
Reducing myocardial infarct size: challenges and future opportunities. Heart (2015) 1.00
HDAC-dependent ventricular remodeling. Trends Cardiovasc Med (2013) 1.00
Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol (2014) 0.98
Cardiac output, at rest and during exercise, before and during myocardial ischemia, reperfusion, and infarction in conscious mice. Am J Physiol Regul Integr Comp Physiol (2013) 0.97
The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.96
Uncoupling of increased cellular oxidative stress and myocardial ischemia reperfusion injury by directed sarcolemma stabilization. J Mol Cell Cardiol (2013) 0.95
Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. J Am Heart Assoc (2013) 0.94
Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol (2014) 0.94
Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection? Br J Pharmacol (2014) 0.93
Controversies in cardiovascular MR imaging: reasons why imaging myocardial T2 has clinical and pathophysiologic value in acute myocardial infarction. Radiology (2012) 0.93
Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy (2015) 0.91
Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion. Basic Res Cardiol (2012) 0.90
Ischaemic conditioning: pitfalls on the path to clinical translation. Br J Pharmacol (2015) 0.89
Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia. J Cardiovasc Pharmacol Ther (2013) 0.89
Blockade of electron transport at the onset of reperfusion decreases cardiac injury in aged hearts by protecting the inner mitochondrial membrane. J Aging Res (2012) 0.88
The treatment of acute myocardial infarction: the Past, the Present, and the Future. Eur Heart J Acute Cardiovasc Care (2012) 0.87
HIF-1α signaling activation by post-ischemia treatment with astragaloside IV attenuates myocardial ischemia-reperfusion injury. PLoS One (2014) 0.87
Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther (2014) 0.85
Biomarkers for ischemic preconditioning: finding the responders. J Cereb Blood Flow Metab (2014) 0.85
Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic syndrome. J Thorac Cardiovasc Surg (2014) 0.84
Myocardial ischemia, reperfusion, and infarction in chronically instrumented, intact, conscious, and unrestrained mice. Am J Physiol Regul Integr Comp Physiol (2012) 0.84
Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke. Exp Neurol (2015) 0.84
Astragaloside attenuates myocardial injury in a rat model of acute myocardial infarction by upregulating hypoxia inducible factor‑1α and Notch1/Jagged1 signaling. Mol Med Rep (2017) 0.82
Proteomic Profiling Reveals Adaptive Responses to Surgical Myocardial Ischemia-Reperfusion in Hibernating Arctic Ground Squirrels Compared to Rats. Anesthesiology (2016) 0.81
9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol (2016) 0.81
Adjuvant cardioprotection in cardiac surgery: update. Biomed Res Int (2014) 0.81
Mitsugumin-53: potential biomarker and therapeutic for myocardial ischemic injury? J Mol Cell Cardiol (2015) 0.79
Discordant signaling and autophagy response to fasting in hearts of obese mice: Implications for ischemia tolerance. Am J Physiol Heart Circ Physiol (2016) 0.79
Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation. Sci Rep (2016) 0.78
Conditioning the heart to prevent myocardial reperfusion injury during PPCI. Eur Heart J Acute Cardiovasc Care (2012) 0.78
Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery. BMJ Open (2015) 0.77
Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes. Exp Diabetes Res (2012) 0.76
The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury. PLoS One (2016) 0.76
Did a classic preconditioning study provide a clue to the identity of the mitochondrial permeability transition pore? Circ Res (2013) 0.76
Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart. Life Sci (2015) 0.76
Chronic kidney disease: the "perfect storm" of cardiometabolic risk illuminates genetic diathesis in cardiovascular disease. J Am Coll Cardiol (2013) 0.75
Bridging the Gap between Translational and Outcome Research in Cardiovascular Disease. Biomed Res Int (2015) 0.75
At the crossroads from bench to bedside: luteolin is a promising pharmacological agent against myocardial ischemia reperfusion injury. Ann Transl Med (2016) 0.75
Phosphomimetic modulation of eNOS improves myocardial reperfusion and mimics cardiac postconditioning in mice. PLoS One (2014) 0.75
Modeling oxygen requirements in ischemic cardiomyocytes. J Biol Chem (2017) 0.75
Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury. PLoS One (2017) 0.75
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 19.82
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med (2000) 13.25
Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation (1999) 11.04
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med (2008) 9.40
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol (2003) 6.27
The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation (1977) 5.67
Postconditioning the human heart. Circulation (2005) 4.35
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation (1993) 3.68
Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res (2004) 3.40
Postconditioning inhibits mitochondrial permeability transition. Circulation (2005) 3.30
Role of the mitochondrial permeability transition in myocardial disease. Circ Res (2003) 3.26
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev (2007) 3.19
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15
The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 3.09
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res (2002) 2.84
Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation (2008) 2.64
Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation (2008) 2.62
Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging (2009) 2.61
Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res (2004) 2.55
Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation (2004) 2.50
Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet (2007) 2.48
Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation (1995) 2.33
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2010) 2.20
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol (2004) 2.18
Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. Circulation (2010) 2.06
Loss of cardioprotection with ageing. Cardiovasc Res (2009) 1.94
Autophagy during cardiac stress: joys and frustrations of autophagy. Annu Rev Physiol (2010) 1.87
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J (2006) 1.86
Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circ Cardiovasc Imaging (2010) 1.85
A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv (2010) 1.70
The quantification of infarct size. J Am Coll Cardiol (2004) 1.67
Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol (2010) 1.66
Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv (2008) 1.63
Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv (2009) 1.60
Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res (2007) 1.57
Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol (2002) 1.51
Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv (2009) 1.51
Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol (2006) 1.50
Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol (2008) 1.43
Autophagy induced by ischemic preconditioning is essential for cardioprotection. J Cardiovasc Transl Res (2010) 1.43
Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther (2010) 1.41
5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol (2010) 1.39
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol (2010) 1.37
The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol (2006) 1.32
Molecular imaging: T2-weighted CMR of the area at risk--a risky business? Nat Rev Cardiol (2010) 1.31
Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation (1994) 1.29
Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J (2008) 1.21
Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal (2010) 1.17
Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Circulation (2000) 1.16
Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 min. Am J Physiol Heart Circ Physiol (2006) 1.13
Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol (2006) 1.01
Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol (2009) 0.95
Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol (2006) 0.93
Mild hypothermia as a cardioprotective approach for acute myocardial infarction: laboratory to clinical application. J Cardiovasc Pharmacol Ther (2010) 0.92
ST-Segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance. Am Heart J (2010) 0.86
Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol (1997) 0.84
Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J (2006) 0.83
Application of technetium-99m sestamibi single photon emission computed tomography in acute myocardial infarction: measuring the efficacy of therapy. Q J Nucl Med Mol Imaging (2010) 0.79
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature (2005) 11.22
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol (2007) 10.24
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med (2008) 9.40
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Human cardiac stem cells. Proc Natl Acad Sci U S A (2007) 7.76
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med (2007) 6.68
Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol (2003) 6.27
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell (2007) 5.85
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A (2007) 5.36
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation (2003) 5.20
Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med (2002) 4.95
Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med (2011) 4.81
Stem cell niches in the adult mouse heart. Proc Natl Acad Sci U S A (2006) 4.58
Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem (2006) 4.57
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Postconditioning the human heart. Circulation (2005) 4.35
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest (2005) 4.14
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation (2005) 4.03
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet (2007) 3.93
Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A (2005) 3.93
Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol (2002) 3.79
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J (2012) 3.78
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78
Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles. J Proteome Res (2009) 3.77
A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science (2007) 3.73
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation (2010) 3.72
Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation (2012) 3.70
Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A (2005) 3.64
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res (2004) 3.63
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med (2015) 3.60
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56
Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res (2013) 3.56
Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson (2013) 3.52
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45
The National Surgical Quality Improvement Program in non-veterans administration hospitals: initial demonstration of feasibility. Ann Surg (2002) 3.44
Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation (2010) 3.42
Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res (2004) 3.40
The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol (2013) 3.39
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Submillisievert median radiation dose for coronary angiography with a second-generation 320-detector row CT scanner in 107 consecutive patients. Radiology (2013) 3.34
Postconditioning inhibits mitochondrial permeability transition. Circulation (2005) 3.30
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med (2007) 3.29
Role of the mitochondrial permeability transition in myocardial disease. Circ Res (2003) 3.26